FDA Grants Orphan Drug Designation to SRF231 for Treatment of Multiple Myeloma

August 2, 2018 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to SRF231 for the treatment of patients with multiple myeloma. SRF231 is a fully human antibody that inhibits the activity of CD47, a protein overexpressed on many types of cancer cells, which prevents them from being engulfed and eliminated by macrophages. “While the potential applications for SRF231 in oncology are quite broad, we are particularly excited about … (leggi tutto)